Survey on the use of Cellworks reports for cancer treatment decisions
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
Avera McKennan Hospital & University Health Center · NCT05308784
This study is trying to see how helpful Cellworks reports are for doctors when making treatment choices for cancer patients who have had genetic testing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 730 (estimated) |
| Sex | All |
| Sponsor | Avera McKennan Hospital & University Health Center (other) |
| Locations | 1 site (Sioux Falls, South Dakota) |
| Trial ID | NCT05308784 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Cellworks Singula™ and Ventura™ reports in guiding treatment recommendations for patients with various types of cancer. It gathers insights from physicians and molecular tumor boards on how these reports influence clinical decision-making. Participants must have undergone next-generation sequencing (NGS) testing and are eligible regardless of their cancer stage. The study focuses on understanding the clinical utility and usability of these reports in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates include patients with any stage of cancer who have had recent NGS testing.
Not a fit: Patients who have not undergone NGS testing or those with very advanced cancer stages may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment decision-making for cancer patients by providing tailored therapy recommendations based on molecular insights.
How similar studies have performed: While the specific approach of using Cellworks reports is relatively novel, similar studies utilizing molecular profiling for treatment decisions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
1. Have any stage of cancer for the indications listed at: https://cellworks.life/mycare101 Patients are eligible at any stage of disease. 2. Expected to be alive 6 months or more 3. Requirements for NGS testing (e.g., panel or whole-exome sequencing): NGS testing has been ordered from or performed by one or more vendors specified at: https://cellworks.life/mycare101 . NGS reports must be ordered or performed within the last 90 days. Cellworks will accept all NGS input formats available, including PDF, VCF, BAM, and FastQ. 4. Requirements for additional laboratory testing If Hematological Indication, Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered If Acute Myeloid Leukemia (AML), FLT3-itd testing has been ordered If Indication is a form of Brain Cancer (e.g., glioblastoma), Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered and MGMT Methylation test has been ordered
Where this trial is running
Sioux Falls, South Dakota
- Avera McKennan — Sioux Falls, South Dakota, United States (RECRUITING)
Study contacts
- Study coordinator: Tobias Meissner, PhD
- Email: tobias.meissner@avera.org
- Phone: 605-322-3894
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pan-cancer